Dlx3 plays a role as a positive regulator of osteoclast differentiation
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Dlx3 is a homeodomain protein and is known to play a role in development and differentiation of many tissues. Deletion of four base pairs in DLX3 (NT3198) is causally related to tricho-dento-osseous (TDO) syndrome (OMIM # 190320), a genetic disorder manifested by taurodontism, hair abnormalities, and increased bone density in the cranium. Although the observed defects of TDO syndrome involves bone, little is known about the role of Dlx3 in bone remodeling process. In this study, we examined the effect of wild type DLX3 (wtDlx3) expression on osteoclast differentiation and compared it with that of 4-BP DEL DLX3 (TDO mtDlx3). To examine whether Dlx3 is expressed during RANKL-induced osteoclast differentiation, RAW264.7 cells were cultured in the presence of receptor activator of nuclear factor-B ligand (RANKL). Dlx3 protein level increased slightly after RANKL treatment for 1 day and peaked when the fusion of prefusion osteoclasts actively progressed. When wtDlx3 and TDO mtDlx3 were overexpressed in RAW264.7 cells, they enhanced RANKL-induced osteoclastogenesis and the expression of osteoclast differentiation marker genes such as calcitonin receptor, vitronectin receptor and cathepsin K. Since osteoclast differentiation is critically regulated by the balance between RANKL and osteoprotegerin (OPG), we examined the effect of Dlx3 overexpression on expression of RANKL and OPG in C2C12 cells in the presence of bone morphogenetic protein 2. Overexpression of wtDlx3 enhanced RANKL mRNA expression while slightly suppressed OPG expression. However, TDO mtDlx3 did not exert significant effects. This result suggests that inability of TDO mtDlx3 to regulate expression of RANKL and OPG may contribute to increased bone density in TDO syndrome patients. Taken together, it is suggested that Dlx3 play a role as a positive regulator of osteoclast differentiation via up-regulation of osteoclast differentiation-associated genes in osteoclasts, as well as via increasing the ratio of RANKL to OPG in osteoblastic cells.
Abstract
Dlx3 is a homeodomain protein and is known to play a role in development and differentiation of many tissues. Deletion of four base pairs in DLX3 (NT3198) is causally related to tricho-dento-osseous (TDO) syndrome (OMIM # 190320), a genetic disorder manifested by taurodontism, hair abnormalities, and increased bone density in the cranium. Although the observed defects of TDO syndrome involves bone, little is known about the role of Dlx3 in bone remodeling process. In this study, we examined the effect of wild type DLX3 (wtDlx3) expression on osteoclast differentiation and compared it with that of 4-BP DEL DLX3 (TDO mtDlx3). To examine whether Dlx3 is expressed during RANKL-induced osteoclast differentiation, RAW264.7 cells were cultured in the presence of receptor activator of nuclear factor-B ligand (RANKL). Dlx3 protein level increased slightly after RANKL treatment for 1 day and peaked when the fusion of prefusion osteoclasts actively progressed. When wtDlx3 and TDO mtDlx3 were overexpressed in RAW264.7 cells, they enhanced RANKL-induced osteoclastogenesis and the expression of osteoclast differentiation marker genes such as calcitonin receptor, vitronectin receptor and cathepsin K. Since osteoclast differentiation is critically regulated by the balance between RANKL and osteoprotegerin (OPG), we examined the effect of Dlx3 overexpression on expression of RANKL and OPG in C2C12 cells in the presence of bone morphogenetic protein 2. Overexpression of wtDlx3 enhanced RANKL mRNA expression while slightly suppressed OPG expression. However, TDO mtDlx3 did not exert significant effects. This result suggests that inability of TDO mtDlx3 to regulate expression of RANKL and OPG may contribute to increased bone density in TDO syndrome patients. Taken together, it is suggested that Dlx3 play a role as a positive regulator of osteoclast differentiation via up-regulation of osteoclast differentiation-associated genes in osteoclasts, as well as via increasing the ratio of RANKL to OPG in osteoblastic cells.
참고문헌 (27)
- Anderson, S.A, "Interneuron migration from basal forebrain to neocortex : dependence on Dlx genes", 278, pp.474476~ (1997)
- Aubin, J.E. Bonnelye, E, "Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption", 11, pp.905~913 (2000)
- Collin-Osdoby, P, "RANKL-mediated osteoclast formation from murine RAW264.7cells.", 80, pp.153~166 (2003)
- Ghanem, N, "Regulatory roles of conserved intergenic domains in vertebrate Dlx bigene clusters", 13, pp.533543~ (2003)
- Ghoul-Mazgar, S, "Expression pattern of Dlx3 during cel diferentiation in mineralized tisues", 37, pp.799~809 (2005)
- Hasan, M.Q, "Dlx3 transcriptional regulation of osteoblast diferentiation : temporal recruitment of Msx2 ,Dlx3 and Dlx5 homeodomain proteins to chromatin of the osteocalcin gene", 24, pp.92489261~ (2004)
- Hasan, M.Q, "BMP2 commitment to the osteogenic lineage involves activation of Runx2 by DLX3 and a homeodomain transcriptional network", 281, pp.40515~40526 (2006)
- Ishii, M, "RANKL-induced expression of tetraspanin CD9 in lipid raft membrane microdomain is essential for cel fusion during osteoclastogenesis", 21, pp.965976~ (2006)
- Koide, M, "Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1alpha through upregulation of osteoclast diferentiation factor and cyclooxygenase-2", 259, pp.97~102 (1999)
- Lacey, D.L, "Osteoprotegerin ligand is a cytokine that regulates osteoclast diferentiation and activation", 93, pp.165~176 (1998)
- Luchin, A, "Genetic and physical interactions between Microphthalmia transcription factor and PU 1 are necessary for osteoclast gene expression and diferentiation", 276, pp.36703~36710 (2001)
- Marks, "The hematogenous origin of osteoclasts experimental evidence from osteopetrotic mice treated with spleen cells from beige mouse donors", pp.1~10 (1981)
- Matsuo, K, "Nuclear factor of activated T-cells(NFAT) rescues osteoclastogenesis in precursors lacking c-Fos", 279, pp.26475~26480 (2004)
- Moraso, M.I, "Regulation of epidermal differentiation by a Distal-less homeodomain gene", 135, pp.1879~1887 (1996)
- Nagai, M, "Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast diferentiation factor regulates osteoclast formation", 257, pp.719~723 (1999)
- Northrop, "NF-AT components define a family of transcription factors targeted in T-cell activation", pp.497~369 502 (1994)
- Otsuka, E, "Treatment of myoblastic C2C12 cels with BMP-2 stimulates vitamin D-induced formation of osteoclasts", 73, pp.72~77 (2003)
- Price, "Identification of a mutation in DLX3 associated with tricho-dento-osseous", pp.563~569 (1998)
- Price, J.A, "A common DLX3 gene mutation is responsible for tricho-dento-osseous syndrome in Virginia and North Carolina families", 35, pp.825~828 (1998)
- Quinn, J.M.W, "A combination of osteoclast diferentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro", 139, pp.4424~4427 (1998)
- Sharma, S.M, "MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast diferentiation", 282, pp.15921~15929 (2007)
- Simonet, W.S, "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density", 89, pp.303~319 (1997)
- Suda, T, "Modulation of osteoclast diferentiation and function by the new members of the tumor necrosis factor receptor and ligand families", 20, pp.345~357 (1999)
- Wright, J.T, "Analysis of the tricho-dento-osseous syndrome genotype and phenotype", 72, pp.197~204 (1997)
- Yasuda, H, "Osteoclast diferentiation factor is a ligand for osteoprotegerin", osteoclastogenesis- inhibitory factor and is identical to TRANCE, pp.1998a[DOI]
- Yasuda, H, "Identity of osteoclastogenesis inhibitory factor a mechanism by which OPG", OCIF inhibits osteoclastogenesis in vitro, 1998b, pp.139, 1329~1337
- Yasuda, H, "Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG", OCIF inhibits osteoclastogenesis in vitro, 1998b, pp.139, 1329~1337